ACTIVE LEARNING TEMPLATE:
Medication
Bruno Dossantos
STUDENT NAME______________________________________
Prednisone
MEDICATION___________________________________________________________________________
REVIEW MODULE CHAPTER____________
Intermediate-acting glucocorticoid
CATEGORY CLASS__Corticosteroid,
_____________________________________________________________________
PURPOSE OF MEDICATION
Expected Pharmacological Action
Decreases inflammation by increasing capillary
permeability and lysosomal stabilization, minimal
mineralocorticoid activity
Therapeutic Use
Severe inflammation, neoplasms, multiple
sclerosis, collagen disorders, dermatologic
disorders, pulmonary fibrosis, asthma
Complications
CNS: Depression, flushing, sweating, headache, mood changes CV: Hypertension,
thrombophlebitis, embolism, tachycardia, fluid retention EENT: Fungal infections,
increased intraocular pressure, blurred vision GI: Diarrhea, nausea, abdominal
distention, GI hemorrhage, increased appetite, pancreatitis INTEG: Acne, poor wound
healing, ecchymosis, petechiae META: Hyperglycemia MS: Fractures, osteoporosis,
weakness MISC: Decreased immune response
Medication Administration
＂ Adult: PO 5-60 mg/day or
divided bid-qid ＂ Child: PO
0.05-2 mg/kg/day divided
1-4×/day
Contraindications/Precautions
Fungal infections, hypersensitivity, Pregnancy, diabetes mellitus, glaucoma,
osteoporosis, seizure disorders, ulcerative colitis, HF, myasthenia gravis,
renal disease, esophagitis, peptic ulcer, cataracts, coagulopathy, abrupt
discontinuation, children, corticosteroid hypersensitivity, Cushing syndrome,
diabetes mellitus, ulcerative colitis, thromboembolism, geriatric patients, acute
MI
Interactions
Increase: tendon rupture—quinolones Increase: side effects—alcohol,
salicylates, NSAIDs, amphotericin B, digoxin, cycloSPORINE, diuretics
Increase: predniSONE action—salicylates, estrogens, NSAIDs, oral
contraceptives, ketoconazole, macrolide antiinfectives Increase: predniSONE
effect—CYP3A4 inhibitors Decrease: predniSONE effect—CYP3A4 inducers
Nursing Interventions
Assess: ＂ Adrenal insufficiency: nausea,
vomiting, anorexia, confusion, hypotension,
weight loss before or during treatment; HPA
suppression may be precipitated by abrupt
withdrawal ＂ Potassium, blood glucose, urine
glucose while patient receiving long-term
therapy; hypokalemia and hyperglycemia;
plasma cortisol with long-term therapy, normal:
138-635 nmol/L SI units drawn at 8 am
Client Education
Evaluation of Medication Effectiveness
Therapeutic response: ease of respirations, decreased
inflammation
ACTIVE LEARNING TEMPLATES
That emergency ID as corticosteroid user
should be carried; provide information
about product being taken and condition ＂
To notify prescriber if therapeutic response
decreases; that dosage adjustment may be
needed ＂ To avoid vaccinations ＂ Not to
discontinue abruptly; adrenal crisis can
result
Therapeutic Procedure
A7
0
